On June 23, 2025, the Ark Innovation ETF (ARKK) was trading at $68.74, marking a 1.49% increase from its previous close. This rise occurred amid market fluctuations, reflecting the volatility associated with its focus on disruptive technologies.
Earlier in 2025, ARKK invested significantly in Beam Therapeutics Inc. (BEAM), a company utilizing AI in gene-editing. Between February 11 and 21, 2025, ARKK acquired 364,120 shares of BEAM, valued at approximately $11.1 million as of February 21, 2025.
Cathie Wood, CEO of Ark Investment Management, continues to invest in AI-driven companies, expressing optimism about AI's long-term potential. Investors should note the inherent risks of high-growth sectors.